GOSERELIN DEPOT IN THE TREATMENT OF PREMENOPAUSAL ADVANCED BREAST-CANCER

被引:65
作者
BLAMEY, RW
JONAT, W
KAUFMANN, M
BIANCO, AR
NAMER, M
机构
[1] NAPLES UNIV,SCH MED 2,DIV MED ONCOL,I-80138 NAPLES,ITALY
[2] CTR ANTOINE LACASSAGNE,DEPT ENDOCRINOL,F-06054 NICE,FRANCE
[3] UNIV HAMBURG,DEPT OBSTET & GYNAECOL,W-2000 HAMBURG 13,GERMANY
[4] UNIV HEIDELBERG,FRAUENKLIN,W-6900 HEIDELBERG,GERMANY
关键词
D O I
10.1016/0959-8049(92)90120-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
333 pre- and peri-menopausal patients with breast cancer entered a programme of open studies on the effect of goserelin. Of the 333 patients, 265 patients were entered into assessable efficacy studies. Efficacy data were analysed from 228 eligible patients receiving 3.6 mg of goserelin administered as a subcutaneous injection of a depot formulation once every 28 days. Mean serum luteinising hormone (LH) and oestradiol concentrations were suppressed by day 22 after the first injection. Subjective response occurred in 68.3% of patients assessed. Objective response (UICC criteria) occurred in 36.4% of patients and the lifetable median duration of response was 44 weeks. Responses were observed in all histological grades of tumour, and regardless of oestrogen receptor status. Treatment was well tolerated with no withdrawals due to possible adverse reactions of which hot flushes (75.9%) and loss of libido (47.4%) were commonly encountered. Goserelin provides an effective well tolerated medical alternative to ovarian ablation in the management of advanced breast cancer.
引用
收藏
页码:810 / 814
页数:5
相关论文
共 21 条
  • [1] Beatson G.T., 1896, LANCET, V15, P153, DOI DOI 10.1016/S0140-6736(01)72307-0
  • [2] A RANDOMIZED COMPARISON OF TAMOXIFEN WITH SURGICAL OOPHORECTOMY IN PREMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER
    BUCHANAN, RB
    BLAMEY, RW
    DURRANT, KR
    HOWELL, A
    PATERSON, AG
    PREECE, PE
    SMITH, DC
    WILLIAMS, CJ
    WILSON, RG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) : 1326 - 1330
  • [3] FRACCHIA AA, 1969, SURG GYNECOL OBSTET, V58, P539
  • [4] HARVEY HA, 1981, ENDOCRINE THERAPY BR, P39
  • [5] ASSESSMENT OF RESPONSE TO THERAPY IN ADVANCED BREAST-CANCER - PROJECT OF PROGRAM ON CLINICAL ONCOLOGY OF "INTERNATIONAL-UNION-AGAINST-CANCER, GENEVA, SWITZERLAND
    HAYWARD, JL
    CARBONE, PP
    HEUSON, JC
    KUMAOKA, S
    SEGALOFF, A
    RUBENS, RD
    [J]. EUROPEAN JOURNAL OF CANCER, 1977, 13 (01) : 89 - 94
  • [6] HOEFFKEN K, 1987, P AM SOC CLIN ONCOL, V6, P204
  • [7] INGLE JN, 1986, J CLIN ONCOL, V4, P178, DOI 10.1200/JCO.1986.4.2.178
  • [8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [9] GOSERELIN, A DEPOT GONADOTROPIN-RELEASING HORMONE AGONIST IN THE TREATMENT OF PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER
    KAUFMANN, M
    JONAT, W
    KLEEBERG, U
    EIERMANN, W
    JANICKE, F
    HILFRICH, J
    KREIENBERG, R
    ALBRECHT, M
    WEITZEL, HK
    SCHMID, H
    STRUNZ, P
    SCHACHNERWUNSCHMANN, E
    BASTERT, G
    MAASS, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) : 1113 - 1119
  • [10] KLIJN JGM, 1984, LHRH ITS ANALOGUES, P425